Navigation Links
Echo Therapeutics, Inc. Announces 2011 Financial Results
Date:3/16/2012

f="http://www.twitter.com/echotx">www.twitter.com/echotx
- Join us on Facebook at www.facebook.com/echotxEcho Therapeutics, Inc.Condensed Consolidated Balance SheetsDecember 31,2011December 31,2010ASSETSCurrent Assets:Cash and cash equivalents

$
8,995,571$
,342,044Other current assets

567,940621,693Total current assets

9,563,5111,963,737Net property and equipment (including assets under capitalized leases)

317,73148,034Other Assets:Intangible assets, net of accumulated amortization

9,625,0009,625,000Restricted cash, deposits and other assets

20,565275,499Total other assets

9,645,5659,900,499Total assets

$  19,526,807$  11,912,270LIABILITIES AND STOCKHOLDERS' EQUITYCurrent Liabilities:Accounts payable

$
365,298$
5,634Deferred revenue

123,708405,454Derivative warrant liability

1,035,3371,544,996Accrued expenses and other liabilities

968,120565,546Total current liabilities

2,492,4633,121,630Deferred revenue, notes payable and capital lease obligation, net of current portion

65,75588,356Total liabilities

2,558,2183,209,986CommitmentsStockholders' Equity:Perpetual redeemable preferred stock, Series B

-2Convertible preferred stock, Series C & D

30,16049Common stock

385,442311,264Additional paid-in capital

98,116,32779,646,385Common stock subscribed for but not paid for or issued

6,667285,000Accumulated deficit

(81,570,007)(71,540,416)Total stockholders' equity

16,968,5898,702,284Total liabilities and stockholders' equity

$  19,526,807$  11,912,270Condensed Consolidated Statements of OperationsYears Ended December 31,20112010Licensing revenue

$
302,059$
225,868Other revenue

145,152202,592Total revenues

447,211428,460Operating Expenses:Research and development

3,796,1272,578,852Selling, general a
'/>"/>

SOURCE Echo Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
3. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
5. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
6. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
9. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
10. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
11. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oct. 21, 2014 Influenza will affect as many ... the United States as high as ... to spread is from person to person in respiratory droplets ... serve way of death, but kills much fewer people each ... done by human fluids including sweat, saliva, blood and other ...
(Date:10/22/2014)... Va. and AUSTIN, Texas ... Inc. and PureMHC LLC today announced they have ... develop novel antibody-based immunotherapies designed to target cancers. ... of phosphorylated peptides displayed on the surfaces of ... phosphopeptide tumor targets (PTTs), derived from proteins that ...
(Date:10/22/2014)... Mass. and SHANGHAI , ... (NASDAQ: FMI ) and WuXi PharmaTech ... a collaboration to offer Foundation Medicine,s comprehensive genomic profiling ... China . Under the terms ... WuXi to perform the laboratory component of Foundation Medicine,s ...
Breaking Medicine Technology:WholeHealth Products is proud to be releasing its Influenza A and B combo test, on the heels of the announcing of its phase 2 completion of the Rapid Ebola Test 2Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 3Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 4Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 5
... , Event to Highlight Progress in Research, Advocacy and New Treatments , ... WASHINGTON , May 11 The National Organization for ... that have brought innovative new treatments to market for rare diseases at the 2010 NORD ... on Tuesday, May 18 . , , ...
... U.S. Food and Drug Administration recently approved an application that permits B. Braun ... Injection USP and Dextrose Injection USP in B. Braun,s DUPLEX® Drug Delivery System ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081022/NYW008LOGO ) ... Used in hospitals and healthcare centers ...
Cached Medicine Technology:NORD to Honor Rare Disease Innovators 2NORD to Honor Rare Disease Innovators 3NORD to Honor Rare Disease Innovators 4FDA Approves Cefepime for Use In B. Braun's DUPLEX(R) System 2FDA Approves Cefepime for Use In B. Braun's DUPLEX(R) System 3
(Date:10/22/2014)... (PRWEB) October 22, 2014 Lintelus, Inc., ... Sr. Vice President of Sales, will be speaking on ... Meetings Technology Expo on October 28, at the Holiday ... hosting a booth as well as a Tech Demo ... Meeting can create a more engaging event experience. , ...
(Date:10/22/2014)... WALTHAM, MA (PRWEB) October 22, 2014 ... developing new solutions for the treatment of bacterial infections, ... J. Sinskey has joined its board of directors. ... Microbiology and Engineering Systems at The Massachusetts Institute of ... the MIT faculty since 1968. Dr. Sinskey also holds ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 ... are only about half as likely as white women to ... indicates, and the racial disparity persists even when donor eggs ... white patients became pregnant after IVF, compared to about 17 ... cycles over two years to tease out the impact of ...
(Date:10/22/2014)... Tara Haelle HealthDay Reporter , ... young adult men may lead to increased blood pressure, according ... a similar rise in blood pressure for young adult women ... young adult women drank lightly or moderately, their risk of ... "This finding parallels studies in older adult men and ...
(Date:10/22/2014)... TUESDAY, Oct. 21, 2014 (HealthDay News) -- Measures taken ... plantation in Ebola-ravaged Liberia may have limited the spread ... researchers report. The Firestone Natural Rubber Co. provides ... and residents of nearby densely populated communities. Between ... and suspected Ebola cases among those 80,000 people. That ...
Breaking Medicine News(10 mins):Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2
... Blanket Limbo to raise funds for amputees DALLAS, Feb. 18 ... arm or a leg. Of those impacted, many find themselves with ... limbs needed to resume their daily lives. , ... awareness to the plight of these amputees and provide them with ...
... save lives by donating blood regularlySEWELL, N.J., Feb. 18 ... February 21, 2009 from 9:00 a.m. to 3:00 p.m. ... To make an immediate appointment for this blood ... )Koerner is battling a type of cancer called Acute ...
... 18 The ,Help is Here Express, bus tour ... February 23-27 at various cities throughout the state ... information on programs that provide prescription medicines for free ... having risen for seven straight months, standing today at ...
... widely used blood pressure medication may be the key ... according to a newly published study by researchers at ... offer the hope of an improved quality of life ... study drew on a hypothesis from previous studies that ...
... Ill., and Osaka, Japan, February 13, 2009 Takeda ... North America, Inc., announced today that the United States ... 40 mg and 80 mg for the chronic management ... medication is the first new treatment option in more ...
... clinicians and researchers in the bone health field ... held from March 18-21 in Athens, Greece. ... four-day meeting which will feature an expanded scientific ... clinically-oriented ,Meet-the-Professor, sessions. The programme is also enhanced ...
Cached Medicine News:Health News:Limbs for Life Foundation to Host 8th Annual Fundraiser and Live Auction 2Health News:Blood Drive Held in Honor of Sewell, NJ Resident - Ellie Koerner 2Health News:Partnership for Prescription Assistance Prepared to Help Texas Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help Texas Workers Hurt by Recession 3Health News:Partnership for Prescription Assistance Prepared to Help Texas Workers Hurt by Recession 4Health News:Blood pressure compound may benefit brain tumor patients 2Health News:Blood pressure compound may benefit brain tumor patients 3Health News:FDA approves ULORIC (febuxostat) for the chronic management of hyperuricemia in patients with gout 2Health News:FDA approves ULORIC (febuxostat) for the chronic management of hyperuricemia in patients with gout 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: